Immunosuppressant Drugs and Covid-19: Associated Risks, Drug-Drug Interactions and Contraindications

Author(s): Debjyoti Talukdar, Diane Ignacio, Madan Mohan Gupta*

Journal Name: Coronaviruses
The World's First International Journal Dedicated to Coronaviruses

Volume 2 , Issue 12 , 2021

Article ID: e070921193747
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Immunosuppressant drugs like Etanercept, Mycophenolate mofetil, Sirolimus, Cyclosporine, and Rituximab can weaken the immune system and make patients susceptible to SARS nCoV-2 virus. These drugs make immunocompromised persons more vulnerable to complications associated with COVID-19. Moreover, it can also increase mortality and morbidity, as a weakened immune system can lead to a longer duration of infection. This study discusses the guidelines on immunosuppressant drugs and their associated risk factors with COVID-19, issued by the U.S CDC (Centers for Disease Control and Prevention), WHO (World Health Organization), U.S FDA (Food and Drug Administration), and other accredited global health organizations. Moreover, it also includes information about pharmaceutical properties, mechanism of action, COVID-19 associated risk factors, adverse drug reactions, contraindications, and drug-drug interactions. Our study will help government partners and international health organizations to understand COVID-19 health risks associated with immunosuppressants. Increased public awareness about effective drug therapy for autoimmune diseases, cancer treatment, immunocompromised, and organ transplant patients will help lower the mortality and morbidity associated with the disease amid the COVID-19 pandemic.

Keywords: COVID-19, immunosuppressant drugs, etanercept, mycophenolate mofetil, sirolimus, cyclosporine, rituximab.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 01 June, 2021
Article ID: e070921193747
Pages: 7
DOI: 10.2174/2666796702666210601125131

Article Metrics

PDF: 12